Cosmo Pharmaceuticals N.V. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was EUR 41.51 million compared to EUR 28.42 million a year ago. Net income was EUR 7.87 million compared to net loss of EUR 5.74 million a year ago. Basic earnings per share from continuing operations was EUR 0.476 compared to basic loss per share from continuing operations of EUR 0.399 a year ago. Diluted earnings per share from continuing operations was EUR 0.476 compared to diluted loss per share from continuing operations of EUR 0.399 a year ago.